AstraZeneca PLC (AZN) annual results, year to 31 December 2022: revenue USD 44,351 million, from the 20-F
AstraZeneca PLC files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2022 it reported revenue of USD 44,351 million, up 18.5% on the year before. Its profit attributable to shareholders was USD 3,288 million, up 2835.7%, and diluted earnings per share USD 2.11.
The year to 31 December 2022, against the year before
| Year to | Dec 2021 | Dec 2022 |
|---|---|---|
| Revenue | 37,417 | 44,351 |
| Cost of sales | 12,437 | 12,391 |
| Gross profit | 24,980 | 31,960 |
| Research and development | 9,736 | 9,762 |
| Selling, general and administrative | 15,234 | 18,419 |
| Operating profit | 1,056 | 3,757 |
| Finance costs | 1,300 | 1,346 |
| Profit before tax | -265 | 2,501 |
| Income tax | -380 | -792 |
| Profit for the year | 115 | 3,293 |
| Profit attributable to shareholders | 112 | 3,288 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2021 | Dec 2022 |
|---|---|---|
| Cash from operations | 5,963 | 9,808 |
| Purchase of property, plant and equipment | 1,091 | 1,091 |
| Free cash flow | 4,872 | 8,717 |
| Dividends paid | 3,856 | 4,364 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2021 | Dec 2022 |
|---|---|---|
| Total assets | 105,363 | 96,483 |
| Equity attributable to shareholders | 39,268 | 37,037 |
| Cash and cash equivalents | 6,329 | 6,166 |
| Borrowings, as filed | 30,781 | 29,232 |
| Lease liabilities | 987 | 953 |
| Trade and other receivables | 9,644 | 10,521 |
| Inventories | 8,983 | 4,699 |
| Goodwill | 19,997 | 19,820 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2021 | Dec 2022 |
|---|---|---|
| Gross margin | 66.8% | 72.1% |
| Operating margin | 2.8% | 8.5% |
| Net margin | 0.3% | 7.4% |
| Free cash flow margin | 13.0% | 19.7% |
| Return on year-end equity | 0.3% | 8.9% |
| Effective tax rate | n/a | -31.7% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022, this page
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017
- Year to 31 December 2016
- Year to 31 December 2015
Source
20-F for the year to 31 December 2022, filed 18 February 2025, accession 0001104659-25-014750: the filing on EDGAR. All of AstraZeneca PLC's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.